Rapid Dose Therapeutics Corp (DOSE) AI Stock Analysis

• Market Cap: C$19.12M
• Dividend Yield: N/A
• Average Volume (3M): 36.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.46
• Revenue Growth: 95.76%
• EPS Growth: 22.56%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 131,886,760
• 10 Day Avg. Volume: 35,351
• 30 Day Avg. Volume: 36,089
• PEG Ratio: -0.67
• Price to Book (P/B): -4.07
• Price to Sales (P/S): 10.16
• P/FCF Ratio: -18.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: C$0.14 ▲(0.00% Upside)

The score is held down primarily by weak financial quality (ongoing losses, cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). A positive partnership extension and commercialization progress provide some upside support, but valuation signals are limited due to losses and no dividend data.

Positive Factors

Strong revenue growth and healthy gross margin

Rapid Dose shows outsized top-line growth from a low base alongside a ~52% gross margin, indicating the core product economics can scale. Durable revenue expansion plus healthy unit margins create a credible path to reduce losses as commercialization and volume increase over months.

Commercialization progress and partnership extension

Extension of a nicotine partnership and active Health Canada submission, clinical work and patent progress represent structural commercial progress. These milestones strengthen revenue visibility, customer credibility and potential licensing or co-development deals, supporting medium-term commercial traction.

Platform-based delivery model serving multiple markets

Owning an oral thin-film delivery platform creates a repeatable, B2B productization route across pharmaceuticals and consumer health. Platform/IP-led businesses can scale via partnerships, licensing and formulation services, diversifying revenue sources and leveraging R&D spend across multiple programs.

Negative Factors

Negative shareholders' equity and high leverage

A negative equity base combined with debt in excess of reported assets materially reduces financial flexibility. This capital structure raises refinancing and dilution risk, limiting the company's ability to fund R&D/commercial rollout without onerous terms or equity issuance over the medium term.

Persistent cash burn and negative operating cash flow

Ongoing negative operating and free cash flows mean the business is not yet self-funding and remains dependent on external financing. Continued cash burn constrains execution, forces prioritization of projects and likely necessitates equity or debt raises that dilute or burden future returns.

Deep, sustained operating losses and weak profitability

Extremely negative margins reflect a cost base far exceeding current revenues. Without substantial scale or margin improvement, profitability visibility remains poor; persistent losses will pressure cash needs and could impede investment in commercialization and product development over the coming quarters.

Rapid Dose Therapeutics Corp Business Overview & Revenue Model

Company Description

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.

How the Company Makes Money

Rapid Dose Therapeutics Corp generates revenue primarily through the sale and licensing of its QuickStrip™ technology. The company partners with pharmaceutical, nutraceutical, and cannabis companies to incorporate QuickStrip™ into their product lines, earning income from manufacturing agreements and royalties. Additionally, Rapid Dose may engage in joint ventures or strategic collaborations to expand its application range and market penetration, further boosting its revenue streams.

Rapid Dose Therapeutics Corp Financial Statement Overview

Summary

Strong revenue growth and solid gross margin (~52%) are outweighed by deeply negative profitability (net margin ~-175%), negative operating cash flow/free cash flow (~-$1.0M TTM), and a stressed balance sheet with negative equity and meaningful debt relative to assets—raising dilution/financing risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is modest (~$2.6M) but shows strong growth (about +636%), and gross margin is healthy at ~52%, suggesting the core product economics can work. However, profitability remains deeply negative: net margin is about -175% TTM with sizable operating losses (negative EBIT and EBITDA margins), indicating the cost base is still far ahead of the current revenue scale. The annual history shows improving revenue versus 2023–2024, but losses persist across periods, which keeps earnings quality and near-term profitability visibility weak.

Balance Sheet

The balance sheet is pressured by negative shareholders’ equity in both TTM (about -$5.9M) and recent annual periods, which materially weakens financial flexibility and raises recapitalization/dilution risk. Debt is meaningful relative to the business size (TTM total debt ~ $5.7M versus total assets ~ $4.2M). While leverage ratios are distorted by negative equity, the overall picture is a highly levered capital structure with limited balance-sheet cushion to absorb ongoing losses.

Cash Flow

Cash generation remains a key weakness: TTM operating cash flow is negative (about -$1.0M) and free cash flow is also negative (about -$1.0M), meaning the company is still consuming cash to operate and invest. There is some improvement in the direction of free cash flow (positive growth off a low base), but cash flow is not yet self-funding. With ongoing losses and cash burn, continued reliance on external financing is likely.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2022	Dec 2020
Income Statement
Total Revenue	2.63M	2.09M	1.02M	1.75M	718.30K	755.20K
Gross Profit	1.36M	1.18M	563.41K	1.34M	372.40K	699.85K
EBITDA	-3.03M	-3.93M	-3.02M	-7.59M	-2.92M	-987.00K
Net Income	-4.59M	-5.40M	-4.31M	-8.49M	-3.81M	-1.80M
Balance Sheet
Total Assets	4.25M	1.63M	1.89M	3.07M	2.25M	3.83M
Cash, Cash Equivalents and Short-Term Investments	8.57K	20.72K	161.06K	34.44K	27.59K	70.26K
Total Debt	5.67M	2.61M	2.45M	1.43M	1.61M	2.06M
Total Liabilities	10.13M	6.84M	5.04M	2.82M	4.92M	5.41M
Stockholders Equity	-5.88M	-5.21M	-3.16M	251.56K	-2.67M	-1.58M
Cash Flow
Free Cash Flow	-965.32K	-1.15M	-2.29M	-3.04M	-863.92K	-1.63M
Operating Cash Flow	-958.68K	-1.15M	-2.29M	-3.00M	-863.92K	-1.62M
Investing Cash Flow	2.54M	-5.74K	0.00	1.85M	0.00	-9.12K
Financing Cash Flow	968.20K	1.01M	2.43M	1.13M	856.53K	1.65M

Rapid Dose Therapeutics Corp Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOSE, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.15, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.62 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOSE.

Rapid Dose Therapeutics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	47 Neutral	C$17.04M	-2.10	―	―	-3.93%	-575.24%
BCT	44 Neutral	C$36.52M	-0.09	-409.25%	―	―	62.01%
HEM	44 Neutral	C$17.91M	-3.26	―	―	―	-24.89%
DOSE	43 Neutral	C$19.12M	-4.34	―	―	95.76%	22.56%

Rapid Dose Therapeutics Corp Corporate Events

Rapid Dose Therapeutics Pays Convertible Note Interest in Shares

Rapid Dose Therapeutics Corp. will issue 362,708 common shares to holders of its secured convertible notes to satisfy approximately $47,154 in quarterly interest accrued as of December 31, 2025, with issuance expected by January 15, 2026. The interest payment in shares stems from an amended and restated note financing originally completed in 2023, under which the company extended the maturity of $3.08 million in promissory notes and associated warrants to November 30, 2026; the notes carry an 18% annual interest rate payable in stock at the Canadian Securities Exchange quarter-end closing price, a structure that preserves cash but dilutes existing shareholders while providing continued support from noteholders.

The most recent analyst rating on (TSE:DOSE) stock is a Hold with a C$0.13 price target. To see the full list of analyst forecasts on Rapid Dose Therapeutics Corp stock, see the TSE:DOSE Stock Forecast page.

Rapid Dose Therapeutics Extends Convertible Notes Maturity Date

Rapid Dose Therapeutics Corp. announced an extension of the maturity date for its secured convertible notes, originally set to mature on November 30, 2025, to November 30, 2026. This extension involves noteholders agreeing to new terms, including an increased interest rate from 12% to 18% per annum and an extension fee payable in common shares. The company also plans to issue common shares to satisfy accrued interest, with securities subject to a hold period. This move is part of a related party transaction involving company insiders and is exempt from certain regulatory requirements.